02509 QYUNS-B
- 13.000
- 0.0000.00%
QYUNS-B News
HK Stock Trading | Qilu Pharmaceutical-B (02509) rose more than 7%. The application for the listing approval of Ustilumab injection was approved.
China Bio Pharmaceutical-B (02509) rose over 7%, as of press time, up 7.69%, at HK$14, with a turnover of 0.451 million HK dollars.
Sorrento Therapeutics-B (02509): QX001S (Selexin, Ustekinumab Injection) obtained the pharmaceutical registration certificate approved and issued by the National Medical Products Administration
Chun Shin Biologics -B (02509) issued an announcement. On November 5, 2024, Sino-American East received the National Pharmaceutical Administration...
Announcement Selection | CNOOC's net income in the first three quarters exceeded 116.6 billion yuan, a year-on-year increase of 19.5%; wuxi apptec orders in hand increased by more than 30% year-on-year.
①CNOOC's net income exceeded 110 billion yuan in the first 9 months, how fast is the growth? ②How is the profit performance of WuXi AppTec's year-on-year growth in hand orders?
China San Bio-B (02509.hong kong): China Securities Regulatory Commission accepts the company's H股 full circulation plan application.
Great Wisdom October 28th | Transtech Bio-B (02509.HK) announced that the China Securities Regulatory Commission has recently accepted the company's shareholders' suggestions to implement the application for full circulation of H shares. According to the relevant application documents, the company has applied to convert the 17,322,400 shares held by these shareholders of the company into H shares and list them on the HKEX, accounting for approximately 7.80% of the company's total issued share capital as of the announcement date. After the full circulation of H shares, all domestic shareholders participating in the full circulation of H shares will still need to comply with the stock lock-up requirements stipulated by the HKEX securities listing rules and applicable laws and regulations.
Hopson Development Holdings Limited-B (02509): Wang Yujiao re-elected as employee representative supervisor.
BBIG Pharmaceutical-B (02509) announced that the company will hold a staff representative congress on October 24, 2024, ...
Third quarter IPO report: Hong Kong stock market once again witnessed billion-dollar projects, the number and amount of Chinese enterprise IPOs rebounded year-on-year
In Q3 2024, a total of 52 Chinese companies successfully IPO'd on A-shares, Hong Kong stocks, and US stocks. The number of IPOs decreased by 52.29% year-on-year, but increased by 18.18% compared to the previous period. In the first three quarters, the number of IPOs of Chinese companies globally decreased by 54.98% year-on-year.
Sudden Movement Spotlight | Biomedical Class B shares rose in the afternoon, LKYG-B up 30%, institutions bullish on sector further recovery space
Biomedical Class B shares rose in the afternoon, as of the time of publication, Lai Kai Medicine-B rose by 27.88%, to 7.89 Hong Kong dollars; YimingAngke-B rose by 17.91%, to 5.86 Hong Kong dollars; Yasheng Medicine-B rose by 5.74%, to 46.95 Hong Kong dollars.
Hong Kong stocks are on the move | Namchong Bio-B (02509) rose more than 7%. Achieved revenue of 44.919 million yuan in the first half of the year. Previously collaborated with huadong medicine.
Tshing Shing Biological - B (02509) rose more than 7%, as of the time of publication, it increased by 7.54% to 24.95 Hong Kong dollars.
QYUNS-B: 2024 INTERIM REPORT
Qyuns Therapeutics Shrinks Loss in H1
Performance: Quanxin Biotech (02509.HK) narrowed its half-year loss to 0.172 billion RMB.
China Medical System Holdings Ltd. - B (02509.HK) announced its interim results for the six months ended in June, with revenue reaching 449.2 million yuan (same below). The loss narrowed from 0.258 billion yuan in the same period last year to 0.172 billion yuan, with a loss per share of 79 cents. No interim dividend will be paid.
China Create Bio-B (02509) released its interim results, achieving revenue of 44.919 million yuan.
Quanxin Biopharmaceutical-B (02509) released the unaudited interim results for the six months ending June 30, 2024,...
Qunxing Biologics-B (02509.HK) announced its interim performance. It continues to optimize the CMC quality management system and improve production efficiency, seeking opportunities for overseas expansion.
On August 15th, Grontmij released an announcement. For a six-month period ending on June 30, 2024, the group's revenue was 449.2 million yuan, which was generated from royalty income and research and development service fees from QX008N and QX004N authorized transactions, reflecting the group's strong research and development capabilities. As of July 31, 2024, the company holds 43 patents in China, including 34 invention patents and 9 utility model patents, and 9 patents overseas. As of the same date, the company also has 46 patent applications in China and overseas awaiting approval.
QYUNS-B: UNAUDITED INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024
Quanxin Biology-B (02509.HK) will hold a board of directors' meeting on August 15 to approve its interim performance.
On August 5th, Guolong Announcement, Bio-B (02509.HK) announced that the company's board of directors meeting will be held on August 15, 2024 to consider and approve the group's six-month interim performance ending on June 30, 2024 and its release, as well as handling other matters.
QYUNS-B: NOTICE OF BOARD MEETING
Hong Kong stocks surge | QX005N, the core product of CHAMPION SCIENCE PHARMA, has made progress in development and potential commercialization, causing the stock to rise more than 8% to a new high of nearly a month.
On July 31, Gelunhui | Quantitative Credit Biotechnology-B (2509.HK) rose 8.47% in the afternoon, reaching a new high of 26.9 Hong Kong dollars in nearly a month. The stock has risen more than 26% in the past three trading days. In terms of news, Quantitative Credit Biotechnology announced recently that it has once again joined hands with Hangzhou Zhongmei Huadong, a wholly-owned subsidiary of Huadong Medicine, to sign a cooperation and market promotion service agreement for QX005N, a recombinant humanized IL-4Rα monoclonal antibody injection developed independently by Quantitative Credit Biotechnology. The announcement stated that the partnership with a large pharmaceutical company with strong development and commercialization capabilities and adequate clinical resources nationwide will accelerate development.
HK stocks surge | Qunxing Life Sciences-B(02509) rose nearly 9% in the afternoon, reached cooperation with huadong medicine on the development and commercialization of QX005N injection.
In the afternoon, Quanxin Biotechnology-B (02509) rose nearly 9%, as of press time, it rose 7.17%, to HKD 24.65, with a turnover of HKD 2.1469 million.
Hong Kong stocks have changed | Qunxin Biotech-B (02509) rose more than 3% and reached a strategic cooperation agreement with Huadong Medicine on QX005N injection.
Quanxin Biotech-B (02509) rose more than 3%, as of press time, up 3.48%, and reported 20.8 Hong Kong dollars, with a turnover of 1.0786 million Hong Kong dollars.
Qyuns Therapeutics Enters Development, Potential Commercialization Partnership for QX005N
Analysis
Price Target
No Data
No Data